This narrative review provides a comprehensive overview of the cardiotoxic profiles of conventional and novel hematological cancer therapies and outlines current recommendations for baseline risk stratification, multimodality imaging surveillance, and biomarker monitoring.
Answers are grounded in this paper and cite their sources.
May inform cardiotoxicity monitoring in hematologic malignancies; leaves open need for prospective validation of imaging and biomarkers.
Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.
No takes yet. Share an insight, caveat, or question.
Mandala et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: